GlassScriptPhysician profile
Katherine C Smith
NPI 1215021001
$986.78
in general payments reported to CMS, 2019-2025
15 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $565 · 2022: $190 · 2023: $84.54 · 2024: $30.91 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $232.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $294.15 | 2021-2024 | |
| Amarin Pharma, INC. | $111.77 | 2021 | |
| Novo Nordisk INC | $103.38 | 2021-2023 | Rybelsus, Ozempic |
| Grt US Holding, INC. | $79.59 | 2022 | |
| Ironwood Pharmaceuticals, INC | $64.19 | 2021-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $63.78 | 2021 | |
| Sumitomo Pharma America, INC. | $60.38 | 2025 | Gemtesa |
| Lilly USA, LLC | $45.57 | 2021-2023 | Mounjaro |
| Pfizer INC. | $35.33 | 2021 | |
| Integra Lifesciences Corporation | $32.70 | 2025 | Integra, Primatrix, Integra Dermal Regeneration Template |
| Abbott Laboratories | $23.86 | 2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $21.21 | 2022 | |
| Astellas Pharma US INC | $19.36 | 2021 | |
| Dexcom, INC. | $16.75 | 2021 | |
| Glaxosmithkline, LLC. | $14.76 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Katherine Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.